Alirocumab in high-risk patients: Observations from the open-label expanded use program

Authors

Charles J Glueck, Jewish Hospital, Cincinnati, OH
Alan Brown, Advocate Lutheran General Hospital, Naperville, IL
Anne C Goldberg, Washington University School of Medicine in St. Louis
James M McKenney, Virginia Commonwealth University
Louis Kantaros, Hudson Valley Heart Center, Poughkeepsie, NY
John Stewart, Sanofi, Quebec
Joseph Elassal, Regeneron Pharmaceuticals, Inc.
Andrew Koren, Sanofi, Bridgewater

Journal

Journal of Clinical Lipidology

Publication Date

5-1-2018

Volume

12

Issue

3

First Page

662

Last Page

668

Document Type

Open Access Publication

DOI

10.1016/j.jacl.2018.01.013

Rights and Permissions

Glueck CJ, Brown A, Goldberg AC, McKenney JM, Kantaros L, Stewart J, Elassal J, Koren A. Alirocumab in high-risk patients: Observations from the open-label expanded use program. J Clin Lipidol. 2018 May - Jun;12(3):662-668. doi: 10.1016/j.jacl.2018.01.013. Copyright 2018 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).https://doi.org/10.1016/j.jacl.2018.01.013Journal of Clinical Lipidology (2018) 12, 662–668

Recommended Citation

Glueck, Charles J; Brown, Alan; Goldberg, Anne C; McKenney, James M; Kantaros, Louis; Stewart, John; Elassal, Joseph; and Koren, Andrew, "Alirocumab in high-risk patients: Observations from the open-label expanded use program." Journal of Clinical Lipidology. 12, 3. 662 - 668. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8762